WebFeb 12, 2024 · No clear consensus exists for managing biochemically recurrent prostate cancer after prostatectomy. Interpretation of new data from the JCOG0401 trial warrants consideration of imaging techniques ... WebFeb 25, 2024 · Decipher Prostate, a 22-gene microarray-based genomic classifier, was clinically validated as a predictor of overall survival (OS) in men with biochemically recurrent prostate cancer after radical prostatectomy (RP), according to an ancillary study of the pivotal phase 3 NRG/RTOG 9601 trial. 1,2 The outcome on the genomic classifier, …
Facebook - National Cancer Institute
WebMay 23, 2024 · A follow-up analysis from the PR-7 trial, in men with biochemically recurrent prostate cancer, found that lower testosterone levels were predictive of improved cancer-specific survival and time to … WebMay 23, 2024 · Biochemically recurrent prostate cancer is an increasingly common disease state, with more than 25,000 cases occurring annually in the United States. Fortunately, progress continues to be made to more effectively identify metastatic … Biochemically recurrent prostate cancer is an increasingly common disease state, … shopeeyou.com
Diagnostic performance of 99mTc-HYNIC-PSMA …
WebAug 20, 2024 · BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant cytotoxic chemotherapy must have been completed > 6 months from day (D)1 of the study; BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: No clinical or radiographic … WebFeb 15, 2024 · PSMA PET has led to earlier detection of biochemically recurrent OMPC, often detecting disease missed by conventional imaging. 1 In small phase 2 trials, MDT based on PET or conventional imaging has been shown to delay the need for ADT and delay/prevent metastatic progression in about 30% of patients with OMPC. 2,4-7 More … WebSince biochemically recurrent prostate cancer is defined by technological limitations of radiographic detection, as new imaging (i.e., PSMA) strategies are developed, it may … shopee卖家中心登录不了